Integrated Filing- Financial

LASA Supergenerics Ltd. announced a board meeting on Feb 13, 2026, approving the financial results for the quarter and half-year ended December 31, 2025. Notably, this specific filing lacks the detailed revenue or profit figures.

Instead, the auditor's review highlights severe challenges: a major uninsured fire loss of approx. 20.57 Cr in May 2025 halted all production, raising 'going concern' doubts.

The company is exploring contract manufacturing/leasing to restart.

Auditors also noted dormant bank accounts and suspended revenue recognition due to force majeure.

Overall, the document reflects extreme operational and financial uncertainties.